UPDATED – Event: Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features (Amsterdam, 29 November 2019)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen. If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Agenda: Committee for Advanced Therapies (CAT) (4 – 6 December 2019)

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

Instruction for the Applicants on how to follow the application status and next steps of the process updated

Agenda: Committee for Orphan Medicinal Products (COMP) (3 – 5 December 2019)

OPP Meeting Summary: EP ENVI Committee – Exchange of views with the Commission on the evaluation of the Union legislation on blood, tissues and cells (3 December 2019)

UPDATED – Agenda: EMA Paediatric Committee (PDCO) (25 – 28 June 2019)

UPDATED – Agenda: EMA Committee for Advanced Therapies (CAT) (6-8 November 2019)

Press Release: Meet the 10 EIC finalists who will pitch at the European Venture Contest

The European Innovation Council (EIC) pilot partnered with TechTour for five exclusive online pitching sessions on Healthtech, Digital Technologies and CleanTech. Between 11-13th November, 40 companies funded by the EIC Pilot participated in the TechTour ePitch, but only 10 winners were selected. The finalists will compete at the finals in the European Venture Contest in Essen, on the 9-10 December.

Press Release: State of Health in the EU: shift to prevention and primary care is the most important trend across countries

Today the European Commission published the reports that depict the profile of health systems in 30 countries. Country Health Profiles are being issued with the Companion Report that shows some of the biggest trends in the transformation of the healthcare systems and draws key conclusions from the Profiles.

UPDATED – Event: Regulatory Science to 2025 (stakeholders for human medicines) (Amsterdam, 18-19 November 2019)

Agenda: Pharmaceutical Committee (17 December 2019)

UPDATED – Comitology Written Consultation: Standing Committee on medicinal products for human use

Agenda: Coreper 1 Meeting (27 November 2019)

Presidency Note: European pharmaceutical policy – strengthened cooperation and coordination with the aim to improve access to medicines

Presidency Note: Economy of Wellbeing – next steps in investing in health as its key component

UPDATED – Agenda: EMA Committee for Advanced Therapies (CAT) (17-19 July 2019)

Comitology Written Consultation: Standing Committee on medicinal products for human use

UPDATED – Comitology Written Consultation: Standing Committee on medicinal products for human use

Comitology Written Consultation: Standing Committee on medicinal products for human use

Event: Future in Medicine – Innovative Cell and Gene Therapies, ATMP Workshop (Brussels, 3 December 2019)

Event: Forward together with innovation: The importance of policy making in the era of personalised medicine (Brussels, 3-4 December 2019)

The event will be held under the auspices of the Finnish Presidency of the EU, which will run from July to December. The Congress is in a focused format to allow concrete issues to be tackled and to have a dialogue with our policy makers. Essentially, this 3rd annual Congress will provide the ideal space to allow for a meeting of minds and expertise and represent a vital opportunity for top-level discussion and the formulation of real action plans, for example in the area of translational research.
Congress will showcase different objectives which both the public and private sector can support, with a view to allowing the EU to present a common objective. Innovation and the incentives for it are key to health and wealth in the current EU-28 (and will be even more important after the UK leaves). It also encourages investment from outside of the EU, which is good for business and jobs. It is clear that innovation needs to soar to new heights, and be implemented and integrated, for the bene t of EU citizens.

Comitology Written Consultation: Standing Committee on medicinal products for human use

Council Conclusions on European Court of Auditors’ Special Report No 07/2019: “EU actions for cross-border healthcare: significant ambitions but improved management required”